Navigation Links
Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
Date:7/3/2012

SAN DIEGO, July 3, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq:  TROV), a developer of trans-renal molecular diagnostics, announced today that they will be collaborating with The University of Texas MD Anderson Cancer Center on the detection of transrenal KRAS mutations in the urine of patients with pancreatic cancer.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

According to recent estimates KRAS mutations are present in more than 90% of pancreatic cancers (1-3), and in 23% of all cancer tissue samples examined by the Sanger Centre (4). An earlier publication in this field used a complicated two-stage PCR assay to detect KRAS mutations in the urine of patients with pancreatic carcinomas (5). Recently, Trovagene successfully completed the analytical development of digital PCR assays for the detection of the most prevalent KRAS mutations, including ones that account for approximately 95% of the KRAS mutations found in pancreatic adenocarcinomas, the most common form of pancreatic cancer. 

Matthew H. Katz, MD, FACS, who will lead the study for MD Anderson, said, "We are pleased to begin this study to detect KRAS mutations in the urine of patients with pancreatic cancer. We will also determine the KRAS mutation status from biopsies taken from the same patients. This will allow an early comparison of mutation detection using biopsy, which samples only a portion of a tumor, with detection using urine, a systemic sampling of the patient."

"The reliable detection and quantification of both KRAS mutations and wild type molecules from urine could eventually lead to a sensitive method for staging tumors before treatment and detecting minimal residual disease after treatment," said Dr. Charlie Rodi, chief technology officer at Trovagene. He added, "The volume of urine that can be collected far outstrips what is available by biopsy or even through blood collection; this may significantly improve detection. In addition, urine is a truly non-invasive sample that could greatly simplify patient monitoring in the future."

  1. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes (1998) Cell  53: 549-554.
  2. Smit V, Boot A, Smits A, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas(1988) NAR  16(16): 7773-7782.
  3. Zhang C, Guo W, Wu J, et al. Differential high-resolution melting analysis for the detection of K-ras codons 12 and 13 mutations in pancreatic cancer (2011) Pancreas 40(8): 1283-1288.
  4. Prevalence of KRAS mutations in various cancers. Sanger COSMIC site. http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=bygene&ln=KRAS&start=1&end=189&coords=AA:AA  
  5. Botezatu I, Serdyuk O, Potapova G, et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism (2000) Clinical Chemistry 46(8): 1078-1084.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contacts
Trovagene, Inc.
Keith McCormick
VP, Commercial Operations
+1 (858) 952-7640
kmccormick@trovagene.com
http://www.trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
2. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
3. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
4. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
5. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
6. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
7. Shingles Vaccine is Safe, According to New Study
8. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... ... 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, joins ... Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, MD, ... Officer at Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May 6 - ... on steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in ... will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
Breaking Medicine News(10 mins):